Davide Matino

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Replacement Therapy

Clinical Practice

Positron Emission Tomography

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Rolf C R Ljung, Davide Matino, Amy D Shapiro
Recombinant factor IX Fc for the treatment of hemophilia B. European journal of haematology 112 (5) (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Rolf C R Ljung, Davide Matino, Amy D Shapiro
Recombinant factor IX Fc for the treatment of hemophilia B. European journal of haematology (2024)
Rolf C R Ljung, Davide Matino, Amy D Shapiro
Recombinant factor IX Fc for the treatment of hemophilia B. European journal of haematology 112 (5) (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia (2024)